Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer

  • New position aimed at attracting, retaining and cultivating a top-notch workforce as Allogene adapts its operations to its next stage of growth

SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer , today announced the appointment of Susan Lundeen as Chief Human Resources Officer effective May 2, 2022. In this newly created role, Susan will oversee Allogene’s human resources efforts as the company continues to advance a rapidly growing AlloCAR T pipeline.

“I am very happy to have Susie join the Allogene team. As we plan our first pivotal trial, expand our pipeline and expand our operations, we need an experienced HR director with a proven ability to develop and align our HR strategy with our business strategy,” said David Chang, MD, Ph.D., President, CEO and Co-Founder. “We want to continue to create a world-class environment for our people and our business to thrive. Susie’s wealth of experience will be key to Allogene’s future success.

Allogene, launched in 2018, quickly established itself as the leader in allogeneic cell therapy. It currently has over 320 employees and was recently named Best Workplace 2022 by BioSpace.

“Allogene’s people are essential to the company’s mission to develop the first AlloCAR T products for cancer patients,” said Susan Lundeen. “I am thrilled to join a diverse and exceptional team and look forward to continuing the incredible work already underway to attract, develop and retain the most talented and diverse talent, so that Allogene can continue to be the best. workplace for years to come.”

Susie has held leadership roles across the full lifecycle of global human resources, talent acquisition, operations, mergers and acquisitions, and business development at several biotechnology companies. Susie most recently worked at Unity Biotechnology where she served as Director of Human Resources for six years. Prior to Unity, Susan was Senior Vice President of Human Resources at Kythera Biopharmaceuticals until its acquisition by Allergan. Susan was responsible for the design and implementation of all personnel systems supporting the business, from early product development through drug approval and eventual commercial launch. From 2005 to 2007, Susan served as Vice President of Human Resources and Administration at Activus Healthcare Solutions, Inc., a healthcare company acquired by PSS, Inc. Prior to this experience, Susan held various positions at Amgen , including an expatriate assignment to support the construction of Amgen’s global distribution facility in the Netherlands. She was also a strategic HR business partner for research and development, and eventually served as senior human resources manager responsible for strategic staffing and succession planning. Susan holds a BA in Psychology and Business Administration from California Lutheran University and is a member of the University’s Board of Trustees.

About Allogen Therapeutics
Allogene Therapeutics, headquartered in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a portfolio of “off the shelf” CAR T cell candidates with the goal of providing cell therapy that is readily available on demand, more reliably, and at lower cost. larger scale for more patients. For more information, please visit www.allogene.comand follow @AllogeneTx on Twitter and LinkedIn.

Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in certain instances, use terms such as “predicts”, “believes”, ” potential”, “proposed”, “continue”, “estimate”, “anticipate”, “expect”, “plan”, “intend”, “may”, “could”, “could”, “will”, “should” or other words that convey uncertainty of future events or results to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, prospects, analyzes or current expectations regarding, among other things: the ability to attract, develop and retain employees; the ability to advance Allogene’s pipeline, including the initiation of a pivotal trial; the ability to develop AlloCAR T products for cancer; and the potential benefits of AlloCAR T products. Various factors could cause Allogene’s expectations to differ from actual results, as further discussed in Allogene’s filings with the Securities and Exchange Commission (SEC), including, without limitation, in its Form 10-K for the fiscal year ended December 31, 2021. Forward-looking statements made in this press release speak only as of the date of this press release. Allogene undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene media/investor contacts:
Christine Cassiano
Head of Communications
(714) 552-0326

[email protected]

main logo


Comments are closed.